Research programme: hepatitis C therapeutics - Genelabs/Genovate Biotechnology/NHRI

Drug Profile

Research programme: hepatitis C therapeutics - Genelabs/Genovate Biotechnology/NHRI

Latest Information Update: 19 Apr 2011

Price : $50

At a glance

  • Originator Genelabs Technologies; Genovate Biotechnology; National Health Research Institutes
  • Developer Genelabs Technologies; Genovate Biotechnology
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 07 Jan 2009 Genelabs Technologies has been acquired by GlaxoSmithKline
  • 24 Jul 2008 Early research in Hepatitis C in Taiwan (unspecified route)
  • 24 Jul 2008 Early research in Hepatitis C in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top